What happened
In a notice initially posted on October 7, 2026, the FDA listed specific lots of intravenous and subcutaneous immune globulin that were voluntarily withdrawn following increased reports of allergic or hypersensitivity reactions. Some of the reported reactions were considered medically significant. The list includes withdrawals dated July and August, as well as Yimmugo lot C795314, with a listed withdrawal date of October 7, 2026.
The FDA instructs holders to check their stock immediately, stop using vials from the listed lots and return them for replacement. This instruction is tied to the identified lots; it is not a withdrawal of every vial sold under those product names.
Why it matters
Allergic and anaphylactic reactions were already known risks of immune-globulin products. What changed is that increased reports for specified lots led to withdrawals and an explicit instruction for holders to stop using those vials. For a facility, the practical difference is an immediate inventory check using the lot number printed on each vial, rather than a decision based on the product name alone.
The lack of a published numerical reaction rate does not mean there is no concern: the FDA has issued a cease-use instruction for the listed lots. At the same time, the notice does not establish that every vial under the same product names has the same reported problem, or explain what caused the increase in reports.
Evidence
The listed lots are Alyglo 394C25018, 394C25019 and 394C25020; Gammaked B13K127733; Gamunex-C B23L053203; and Yimmugo C795145, C795165 and C795314. These identifiers determine which inventory is covered by the FDA’s instruction to cease use.
The FDA says allergic and anaphylactic reactions are known risks of immune-globulin products, but reports for the listed lots occurred at a higher rate. The consulted notice does not give the number of reactions, the number of doses administered or a lot-by-lot incidence estimate. The reports explain the concern prompting the withdrawals; without those figures or an identified cause, they do not establish a numerical risk for an individual vial.
What remains unknown
The notice does not identify why reports were higher for these lots or establish how their risk compares with that of unaffected lots. It also does not provide the reaction and dose counts needed to calculate an incidence rate. Those uncertainties limit conclusions about cause and comparative safety, but they do not qualify the FDA’s direction to stop using the listed inventory.
Who may be affected
Facilities holding any of the specified immune-globulin lots and people who might otherwise receive vials from those lots.
AXIONOVA connection
This signal depends on keeping the product and lot identifiers together. A product name alone cannot tell a facility whether a vial is covered by the cease-use instruction. Matching inventory against the FDA’s list is the immediate decision point; extending the instruction to unlisted lots would go beyond what the notice establishes.
What ALETHA can explain
Aletha can explain why a lot-specific withdrawal requires matching vial identifiers, how it differs from withdrawing an entire product, and why increased adverse-event reports without reaction and dose counts do not provide an incidence rate.
Action posture
Urgent official safety direction: The FDA directs immediate stock examination and cessation of use for specified affected lots.